This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.8 (other specified disorders of carbohydrate metabolism; includes disorders of oxalate metabolism) | Special Copayment Reduction: V117 |
| B. Synonyms | Hyperoxaluria, primary hyperoxaluria type 1 (PH1; AGXT deficiency), primary hyperoxaluria type 2 (PH2; GRHPR deficiency), primary hyperoxaluria type 3 (PH3; HOGA1 deficiency), oxalosis, primary hyperoxaluria |
| C. Adult onset | Likelihood of first presentation in adulthood: high — about 10–25% of PH1 is first diagnosed in adulthood (especially in the 20s–40s) with recurrent nephrolithiasis or progressive chronic kidney failure. Many PH3 cases improve after childhood, but recurrence is possible in some adults. Undiagnosed PH1 is sometimes discovered in adult dialysis patients. |
| 1. History | 1925 first description of PH → 1957 Archer/Doyle, discovery of the PH1 enzyme deficiency → 1990s cloning of AGXT and GRHPR → 2010 discovery of HOGA1 (PH3) → 2020 FDA approval of lumasiran (siRNA, Oxlumo) → 2022 nedosiran (AGXT gene therapy trial). |
| 2. Causes | PH1: AGXT deficiency (deficiency of hepatic peroxisomal alanine:glyoxylate aminotransferase) → excessive conversion of glyoxylate → oxalate. PH2: GRHPR deficiency. PH3: HOGA1 deficiency. All autosomal recessive. Oxalate overproduction → calcium oxalate deposition in the kidneys and throughout the body (oxalosis). |
| 3. Genetics | AGXT (PH1): 2q37.3, 11 exons. p.Gly170Arg (c.508G>A) is a founder variant in about 30–40% of Western PH1. p.Phe152Ile (c.454T>A) is frequent in the Mediterranean. Korean and Japanese PH1: p.Gly82Glu, etc. GRHPR (PH2): 9p13.2. HOGA1 (PH3): 10q24.2. More than about 200 AGXT variants reported. |
| 4. General epidemiology | PH1 prevalence about 1–3/1,000,000. PH2 about 1/5,000,000–1/10,000,000. PH3 about 1–2/1,000,000. Among all PH1 patients, childhood onset about 50%, adult onset about 25%. PH1 accounts for about 0.5–1% of dialysis patients. Relatively frequent in the Middle East and North Africa (consanguineous marriage). |
| 5. Pathophysiology | AGXT/GRHPR/HOGA1 deficiency → inability to process glyoxylate in the liver → oxalate overproduction → excessive urinary oxalate excretion → calcium oxalate stones (nephrolithiasis) and nephrocalcinosis in the kidneys → declining renal function → systemic oxalate deposition (oxalosis): bone, joints, heart, blood vessels, eyes, skin. |
| 6. Symptoms | Nephrolithiasis (recurrent urinary stones), hematuria, renal colic, nephrocalcinosis. With progression: declining renal function, chronic kidney disease (CKD). Systemic oxalosis: bone pain and pathological fractures, anemia (red marrow involvement), arrhythmia and heart failure, retinal deposits, skin ulcers. |
| 7. Signs | Renal ultrasound: nephrocalcinosis and stones. Urine: hyperoxaluria (>40 mg/1.73m²/day). Elevated serum oxalate (in kidney failure). Elevated urinary glycolate (PH1). Elevated urinary L-glycerate (PH2). Declining renal function (elevated creatinine). Bone marrow biopsy: calcium oxalate crystals. |
| 8. Screening | 24-hour urine oxalate measurement in patients with recurrent calcium oxalate nephrolithiasis. Differential diagnosis of nephrolithiasis first presenting in childhood. AGXT/GRHPR/HOGA1 gene panel analysis in unexplained nephrocalcinosis and early CKD. Family history-based genetic testing. |
| 9. Diagnosis | Confirmation of elevated 24-hour urine oxalate. Urinary glycolate (suggests PH1), L-glycerate (suggests PH2), CHMS (suggests PH3). Plasma oxalate measurement. Genetic analysis (AGXT/GRHPR/HOGA1). Liver biopsy for AGT enzyme activity and immunohistochemistry (confirms PH1, optional). Pyridoxine (B6) response testing (PH1). |
| 10. Treatment | Conservative: adequate fluid intake (3L/m²/day), neutral phosphate and potassium citrate (stone inhibition). PH1 pyridoxine (B6) responders: high-dose B6. PH1 RNA interference: lumasiran (Oxlumo, nedosiran approved 2022). PH1 with progressive CKD: combined liver-kidney transplantation or liver transplantation followed by kidney transplantation. Regular hemodialysis (adjunct for oxalate removal). Gene therapy trials in progress. |
| 11. Prognosis | PH1: without early treatment, about 50% reach end-stage kidney failure before age 25. Lumasiran markedly reduces urinary oxalate → delays progression. Recurrence suppressed after liver-kidney transplantation. PH2: relatively mild, good prognosis. PH3: mostly mild, some improve after childhood. |
| 12. Prevention | Education on adequate fluid intake, dietary oxalate restriction, appropriate calcium intake, early administration of lumasiran, regular monitoring of renal function, genetic counseling and family genetic testing. |
| 13. References | Cochat P et al. Nephrol Dial Transplant 2012 and 9 others |
The history of primary hyperoxaluria (PH) began in 1925 when the Danish physician Rosennow reported the case of a child with calcium oxalate crystal deposition throughout the body. By the 1950s, dozens of similar cases had been reported, commonly described as characterized by the clinical triad of recurrent nephrolithiasis, nephrocalcinosis, and early kidney failure.
In 1957, Archer and Doyle systematically measured that urinary oxalate excretion in PH patients was 5–10 times or more above normal, establishing the concepts of 'oxalosis' and 'hyperoxaluria'. In the 1960s, two subtypes were found to exist. It was confirmed that glycolate is excessively excreted in the urine in PH1 and L-glycerate in PH2, enabling biochemical distinction of the two subtypes.
In 1986, Heaxt et al. discovered that hepatic peroxisomal alanine:glyoxylate aminotransferase (AGT, AGXT) is deficient or mistargeted in PH1. This was a key discovery for a fundamental understanding of the pathophysiology of PH1. In the 1990s, the AGXT gene (2q37.3) and the GRHPR gene (9p13.2) were cloned, after which molecular diagnosis became possible. In 2010, Esteban et al. (Belostotsky, Bergstein) discovered HOGA1 (10q24.2) as the causative gene of a new third subtype, PH3.
In terms of treatment, the discovery in the 1980s–90s that high-dose pyridoxine (vitamin B6) reduces urinary oxalate in some PH1 patients was an important clinical observation. This is explained by the mechanism that, because AGXT uses pyridoxal 5'-phosphate (PLP, the active form of B6) as a cofactor, raising PLP concentrations in certain misfolding or mistargeting variants can restore residual AGT activity.
In November 2020, the FDA approved lumasiran (Oxlumo) as a treatment for PH1. Lumasiran is an siRNA (small interfering RNA) therapy targeting hydroxyacid oxidase 1 (HAO1) in the liver; it inhibits HAO1 to block glyoxylate production itself. The ILLUMINATE-A, B, and C trials demonstrated excellent efficacy, with urinary oxalate reduced by about 65–72% in pediatric and adult PH1 patients. In 2022, nedosiran received FDA approval as a second siRNA therapy covering PH1, 2, and 3. AAV-based AGXT gene therapy is currently also showing promising early results in phase 1/2 trials.
Primary hyperoxaluria (PH) is an autosomal recessive genetic disorder in which deficiency of hepatic enzymes that process glyoxylate leads to overproduction of oxalate, with calcium oxalate deposition in the urine and throughout the body. To date, three genetic subtypes have been established.
PH1 — AGXT deficiency: the most common and most severe subtype, in which pathogenic variants in the AGXT gene (2q37.3) cause deficiency or loss of function of hepatic peroxisomal alanine:glyoxylate aminotransferase (AGT). AGT, using pyridoxal 5'-phosphate (PLP) as a cofactor, catalyzes the transamination of glyoxylate with alanine to convert it to glycine. When AGT is deficient, glyoxylate cannot be detoxified, and the pathway in which it is oxidized to oxalate by hepatic lactate dehydrogenase (LDH) becomes dominant. As a result, oxalate is overproduced and excreted in large amounts in the urine.
Notably, in about one-third of PH1, the AGT protein is mistargeted to mitochondria instead of normal peroxisomes. This occurs because a domain resembling a mitochondrial targeting sequence is activated by certain variants, so AGT becomes located in the mitochondrial compartment where it cannot function. Pyridoxine (B6)-responsive PH1 occurs mainly in this mistargeting subtype.
PH2 — GRHPR deficiency: variants in the GRHPR gene (9p13.2) cause deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR). GRHPR reduces glyoxylate to glycolate and hydroxypyruvate to L-glycerate. In GRHPR deficiency, glyoxylate accumulates excessively and is converted to oxalate, and L-glycerate is excessively excreted in the urine. The clinical course is milder than PH1.
PH3 — HOGA1 deficiency: variants in the HOGA1 gene (10q24.2) cause deficiency of 4-hydroxy-2-oxoglutarate aldolase (HOGA). HOGA catalyzes the last step of the hydroxyproline metabolic pathway in mitochondria. In its deficiency, CHMS (an intermediate presumed to be a precursor of 3-carboxy-2-hydroxy-5-methylenehexanedioate) accumulates, which is thought to indirectly increase glyoxylate production in the hepatocyte cytoplasm. PH3 is the mildest of the three subtypes and sometimes improves spontaneously after childhood.
The AGXT gene is located on chromosome 2q37.3 and has 11 exons, spanning about 10 kb in total. The translation product is a 392-amino-acid AGT monomer, which functions as a homodimer and is transported to peroxisomes by a peroxisomal targeting sequence (PTS1, C-terminal AKL tripeptide). More than 200 pathogenic variants have been reported worldwide.
Major AGXT variants: p.Gly170Arg (c.508G>A) — the most common single variant, found in about 30–40% of Western PH1 patients, associated with the mitochondrial mistargeting type. p.Ile244Thr (c.731T>C) — the second most common variant in Europe. p.Phe152Ile (c.454T>A) — a founder variant frequent in the Mediterranean (Italy, Spain). c.33_34insC (exon 1 insertion) — reported in some Asian patients. In Korean and Japanese patients, p.Gly82Glu, p.Gly170Arg, etc. have been reported, but systematic studies of the variant spectrum are limited.
Pyridoxine responsiveness and genotype: among AGXT variants, mitochondrial mistargeting is enhanced when the p.Pro11Leu polymorphism coexists with certain mistargeting variants (including p.Gly170Arg). High-dose pyridoxine (B6) acts as a pharmacological chaperone that increases AGT protein stability and induces return to peroxisomes in some mistargeting variants, restoring residual AGT activity. A pyridoxine response rate of about 20–30% is reported in patients with combined p.Gly170Arg/p.Pro11Leu.
GRHPR (PH2): 9p13.2, 9 exons. The c.103delG (p.Gly35Valfs) variant is frequent in Northern Europe. HOGA1 (PH3): 10q24.2, 7 exons. The c.700+5G>T variant is found at high frequency in Ashkenazi Jews. All three genes are inherited in an autosomal recessive manner. NGS-based PH gene panel (AGXT+GRHPR+HOGA1) analysis is currently the diagnostic standard.
Primary hyperoxaluria (PH) is a very rare disease with an overall prevalence of about 1–3/1,000,000 births (based on PH1). PH1 accounts for about 70–80% of all PH, PH2 about 10–20%, and PH3 about 10–15%.
Distribution by ethnicity: PH1 prevalence is relatively high in the Middle East (Iraq, Iran, Jordan, Tunisia) and North Africa, because of the high rate of consanguinity in these regions. In some regions, PH1 accounts for more than 10% of all pediatric end-stage kidney failure. In Europe, PH1 accounts for about 1–3% of the causes of pediatric end-stage kidney failure. In Ashkenazi Jews, the frequency of the PH3 c.700+5G>T founder variant is high, so the proportion of PH3 is relatively high.
There are no accurate prevalence data for PH in Korea, but rare cases have been reported from specialized nephrolithiasis clinics and pediatric nephrology departments. It is estimated that there are a considerable number of undiagnosed cases in which PH is not considered as a cause of recurrent calcium oxalate nephrolithiasis, nephrocalcinosis, and early kidney failure. Cases in which PH1 is belatedly diagnosed as the cause of unexplained kidney failure in adult dialysis patients are reported worldwide, and in such cases systemic oxalosis has already progressed considerably. Under the Special Copayment Reduction (V117) registration system, management is centered on nephrology and pediatric nephrology.
Age of onset of PH1: infantile onset (severe infantile oxalosis) about 10%, childhood onset about 40–50%, and adult onset about 25–30%. Adult-onset PH1 often first presents with recurrent calcium oxalate nephrolithiasis or unexplained progressive chronic kidney failure, so raising awareness among urologists and nephrologists is important.
The core pathophysiology of primary hyperoxaluria is oxalate overproduction due to enzyme deficiency in the hepatic glyoxylate detoxification pathway. Oxalate is not enzymatically degraded in the human body and is removed only by urinary excretion via the kidneys. Therefore, oxalate overproduced in the liver travels through the bloodstream to the kidneys and is excreted in the urine; in this process, it binds calcium ions in the renal tubular lumen to form poorly soluble calcium oxalate crystals.
Calcium oxalate crystal formation in the kidney: when the urinary oxalate concentration exceeds a threshold, it binds calcium ions to form calcium oxalate crystals in monohydrate (whewellite) and dihydrate (weddellite) forms. These crystals deposit in tubular cells and exert direct toxicity (oxidative stress, cell membrane damage, apoptosis) or form stones. When crystals accumulate in the tubular basement membrane and interstitium (nephrocalcinosis), chronic inflammation and fibrosis progress and renal function gradually declines.
Systemic oxalosis: when renal function declines, renal excretion of oxalate decreases and the plasma oxalate concentration rises sharply. When plasma oxalate exceeds a threshold (about 30 μmol/L), calcium oxalate crystals begin to deposit in extrarenal tissues as well. The main deposition sites are bone (bone marrow and cortical bone), joints (articular cartilage), myocardium and the conduction system, vessel walls, the retina, and skin. Bone deposition causes severe bone pain and pathological fractures, and bone marrow deposition leads to impaired red blood cell production, worsening anemia. Deposition in the myocardium and conduction system causes fatal cardiac arrhythmias and heart failure.
Molecular mechanism of PH1 (AGXT deficiency): normally, AGT converts glyoxylate to glycine (transamination) within peroxisomes, processing it through a harmless pathway. When AGT is deficient or mistargeted to mitochondria, LDH (lactate dehydrogenase) in the hepatocyte cytoplasm oxidizes glyoxylate to oxalate. At the same time, some glyoxylate is also converted to glycolate, increasing urinary glycolate, which is a specific biochemical marker of PH1.
Mechanism of lumasiran (siRNA): HAO1 (hydroxyacid oxidase 1) is an enzyme that oxidizes glycolate to glyoxylate in hepatic peroxisomes and is the main upstream source of the glyoxylate that accumulates excessively due to AGT deficiency in PH1. Lumasiran is delivered specifically to hepatocytes via the hepatocyte GalNAc (N-acetylgalactosamine) receptor and selectively degrades HAO1 mRNA (RNA interference), suppressing HAO1 expression by 80–90% and thereby fundamentally blocking glyoxylate production. Because this mechanism works regardless of the AGXT variant, it is effective in all PH1 patients (both pyridoxine-responsive and non-responsive).
The clinical symptoms of primary hyperoxaluria vary according to subtype and renal function status.
Nephrolithiasis and renal colic: the most common initial symptom; renal colic (flank pain, radiating pain, hematuria) due to recurrent urinary stones occurs repeatedly. Calcium oxalate stones are radiopaque and therefore visible on plain abdominal X-ray or CT. Early age at first episode and frequent recurrence (especially in PH1) are clues that distinguish it from idiopathic stones. When nephrolithiasis is first experienced in childhood or adolescence, PH should be actively considered in the differential.
Nephrocalcinosis: calcium oxalate crystals deposit throughout the renal parenchyma, causing nephrocalcinosis. Increased renal echogenicity or calcification shadows are seen on renal ultrasound or CT. Nephrocalcinosis is an important factor that accelerates the decline of renal function.
Progressive chronic kidney disease (CKD): in untreated PH1, renal damage from nephrocalcinosis and recurrent stones accumulates and CKD progresses over years to decades. About 50% of PH1 is reported to reach end-stage renal disease (ESRD) before age 25. In the infantile-onset form (severe infantile oxalosis), renal function is rapidly lost within months to a few years after birth.
Symptoms of systemic oxalosis: when renal function declines markedly (glomerular filtration rate < 30 mL/min/1.73m²), plasma oxalate rises and systemic deposition begins. ① Bone symptoms: severe bone pain, pathological fractures, growth retardation. ② Blood: reduced red blood cell production due to bone marrow deposition of calcium oxalate (anemia, transfusion dependence). ③ Heart: conduction abnormalities (QT prolongation, complete atrioventricular block), hypertrophic or dilated cardiomyopathy, heart failure. ④ Skin: livedo reticularis, skin ulcers, skin nodules (calcium deposits). ⑤ Eyes: calcium oxalate deposition in the retinal macula (reduced vision, glittering crystals observed).
Renal signs: nephrocalcinosis (parenchymal calcification) and stones (ureteral/renal calculi) on renal ultrasound/CT. Markedly increased renal echogenicity. Evidence of recurrent urinary tract infection (pyuria, bacteriuria). Elevated creatinine and BUN (declining renal function). Proteinuria (glomerular damage).
Urine tests: elevated 24-hour urine oxalate (normal < 40 mg/1.73m²/day; rises to 100–400 mg/1.73m²/day in PH1). Elevated urinary glycolate (specific to PH1 — normal < 70 mg/g creatinine). Elevated urinary L-glycerate (specific to PH2). Elevated urinary glycerate and CHMS (reference for PH3). Calcium oxalate crystals in urine sediment (envelope-shaped).
Signs of systemic oxalosis: livedo reticularis and skin nodules on the skin. On eye examination, calcium oxalate crystals around the macula and optic nerve (glittering golden or white deposits). ECG: QT prolongation, atrioventricular block, intraventricular conduction disturbance. Echocardiography: hypertrophic or dilated cardiomyopathy. Bone marrow biopsy: calcium oxalate crystals in a starburst pattern (marrow infiltration, evaluation of the cause of anemia). X-ray: bone sclerosis, sclerotic changes, pathological fractures.
Plasma oxalate measurement: in PH1 patients with advanced CKD, plasma oxalate rises to ≥30 μmol/L (normal < 10 μmol/L) and serves as an indicator of systemic deposition. Plasma oxalate measured before and after dialysis is also used to assess oxalate removal efficiency.
There is no universal newborn screening for primary hyperoxaluria, and active differential testing according to the clinical situation is needed.
Screening in recurrent nephrolithiasis: 24-hour urine oxalate measurement is performed in all patients with recurrent calcium oxalate nephrolithiasis. If urinary oxalate is ≥40 mg/1.73m²/day, differentiation of primary hyperoxaluria including PH is needed. In particular, suspicion of PH is high with ① onset in childhood, ② bilateral involvement, ③ frequent episodes (≥2 per year), ④ family history, and ⑤ accompanying nephrocalcinosis.
Screening in unexplained renal function decline: to differentiate PH in unexplained CKD or nephrocalcinosis, 24-hour urine oxalate, urinary glycolate, L-glycerate, and plasma oxalate are measured. If a dialysis patient has unexplained kidney failure, plasma oxalate is measured with some dialysis withheld before sampling, or calcium oxalate crystals are confirmed in tissue (bone biopsy or fat biopsy).
Gene-based screening for PH1: AGXT, GRHPR, and HOGA1 gene panel analysis (NGS) is performed, and confirmation of biallelic variants is the method of definitive diagnosis. Being noninvasive, rapid, and highly specific, it is recommended as the first-line confirmatory test in patients with clinically suspected PH. Identifying the type of AGXT variant is also important for predicting pyridoxine responsiveness.
Family history-based screening: performing early genetic testing in the siblings and children of patients diagnosed with PH to detect asymptomatic affected individuals and starting early fluid intake education and lumasiran treatment is beneficial for protecting renal function.
Definitive diagnosis of primary hyperoxaluria is made by a combination of confirmation of clinical and biochemical findings and molecular genetic testing.
24-hour urine test: 24-hour urine oxalate (normal < 40 mg/1.73m²/day or < 45 mg/day in adults; 100–400 mg or more in PH1), urinary glycolate (specifically elevated in PH1), urinary L-glycerate (specifically elevated in PH2), and urinary creatinine are measured simultaneously. Urinary calcium, phosphate, citrate, and uric acid are also measured for a comprehensive assessment of stone risk factors.
Plasma oxalate measurement: plasma oxalate measurement is essential in patients with renal function decline of CKD stage 2 or higher (because it accumulates in plasma when urinary excretion decreases). Plasma oxalate > 30 μmol/L indicates a risk of systemic deposition, and > 60 μmol/L requires aggressive treatment.
Genetic analysis: confirmation of biallelic variants by AGXT+GRHPR+HOGA1 NGS panel analysis is the standard for definitive diagnosis. Identifying the type of AGXT variant directly affects prediction of pyridoxine responsiveness and application of lumasiran treatment. If no variant is identified, whole-exome sequencing (WES) is added.
Pyridoxine response test: in PH1 patients, high-dose pyridoxine (2–5 mg/kg/day, maximum 200 mg/day) is given for 3–6 months, and if 24-hour urine oxalate decreases by ≥30%, the patient is classified as a pyridoxine responder. The pyridoxine-responsive form occurs mainly with AGXT mistargeting variants (combined p.Gly170Arg/p.Pro11Leu), and in this case pyridoxine is given long term.
Liver biopsy — AGT activity and immunohistochemistry (optional): performed when definitive diagnosis by genetic analysis is difficult or when a liver biopsy is needed to assess pyridoxine responsiveness. Measurement of AGT activity in fresh liver tissue (less than 10% of normal = confirmed PH1) and AGT immunohistochemistry (distinguishing peroxisomal vs mitochondrial targeting patterns) are possible.
Treatment of primary hyperoxaluria consists of conservative treatment, pyridoxine (PH1 responders), RNA interference therapy (lumasiran/nedosiran), organ transplantation, and dialysis support.
Conservative treatment — fluid intake and stone inhibition: adequate fluid intake (target urine volume ≥3L/m²/day) is the most important basic treatment. Fluid intake dilutes the urinary oxalate concentration to keep it below the threshold for crystal formation. Patients are taught to drink fluids at night as well. Neutral phosphate (sodium/potassium phosphate) raises the urinary phosphate concentration and inhibits calcium oxalate crystallization. Potassium citrate alkalinizes the urine and forms calcium complexes, helping inhibit stones. Dietary oxalate restriction (avoiding high-oxalate foods such as spinach, almonds, and tea) may help, but because the main cause of PH is endogenous oxalate overproduction, dietary restriction alone is insufficient. Calcium should be consumed in adequate amounts (paradoxical effect of increased intestinal oxalate absorption when calcium is deficient).
Pyridoxine (vitamin B6): a pyridoxine response test is performed in all PH1 patients, and high doses (2–5 mg/kg/day) are given long term to responders (≥30% reduction in urinary oxalate). Pyridoxine supplies PLP, the cofactor of AGT, maximizing residual AGT activity and partially correcting mistargeting. No effect in PH2 or PH3.
RNA interference therapy: Lumasiran (Oxlumo): a GalNAc-siRNA targeting HAO1. By inhibiting HAO1 and fundamentally blocking glyoxylate production, it reduces urinary oxalate by about 65–72% (ILLUMINATE-A/B/C trials). It is given by subcutaneous injection (monthly → quarterly for maintenance) to children aged 6 years and older and adults with PH1. Effective in both pyridoxine responders and non-responders. Nedosiran (Rivfloza): a GalNAc-siRNA targeting hepatic LDHA; by inhibiting LDHA it blocks the conversion of glyoxylate to oxalate. Usable in all of PH1, 2, and 3; FDA approved in 2022. Monthly subcutaneous injection.
Liver transplantation and combined liver-kidney transplantation (PH1): in PH1, the liver is the only major organ with the defective enzyme (AGT), so liver transplantation normalizes AGT and fundamentally corrects oxalate overproduction. When renal function has declined (GFR < 20 mL/min/1.73m²), combined liver-kidney transplantation (CLKT) is the standard treatment. Isolated kidney transplantation is contraindicated without liver transplantation because the disease recurs. With the advent of lumasiran, the time when transplantation is needed may be delayed, but CLKT is required when renal function has already been lost. Liver transplantation is generally not needed in PH2 and PH3.
Dialysis: oxalate is partly removed by dialysis, but because production exceeds removal, plasma oxalate continues to rise. Dialysis is used as a bridge therapy before transplantation, and high-frequency dialysis (daily hemodialysis or day-and-night dialysis) is more effective for oxalate removal than conventional dialysis.
Prognosis of PH1: before the introduction of lumasiran, the prognosis of PH1 was poor, and about 50% of untreated PH1 patients reached end-stage kidney failure before age 25. The infantile-onset form (severe infantile form) mostly progressed to kidney failure within a few years. After successful combined liver-kidney transplantation, the 10-year survival rate improved to about 80% or more, but when systemic oxalosis has already progressed, deposited material remains in the kidneys and other organs even after transplantation and is slowly resorbed over several years.
Prognosis of PH1 in the lumasiran era: in the ILLUMINATE trials, lumasiran was confirmed to markedly reduce urinary oxalate and contribute to preserving renal function in PH1 patients not requiring transplantation. Starting lumasiran early (before renal function declines) is expected to greatly suppress stone formation and renal function decline. Long-term follow-up data on how much lumasiran changes actual clinical outcomes are accumulating.
Prognosis of PH2: the clinical course is milder than PH1, and renal function is often preserved into adulthood. Recurrent nephrolithiasis is the main cause of morbidity, and CKD progresses in some. Systemic oxalosis is rare.
Prognosis of PH3: the mildest of the three subtypes, with symptoms easing after childhood in many patients. Recurrent nephrolithiasis occurs, but renal function decline is rare. Because recurrence in adulthood can occur, follow-up is needed.
Primary prevention of primary hyperoxaluria is achieved through genetic counseling and genetic testing. In subsequent pregnancies in families who have had a child with PH, affected births can be prevented through prenatal genetic diagnosis (CVS or amniocentesis) and PGT.
Fluid intake education: adequate fluid intake (target urine volume ≥3L/m²/day) is thoroughly taught immediately upon diagnosis. Fluid intake is the most cost-effective and effective stone prevention strategy. Nighttime fluid intake and fluid replacement during exercise are particularly emphasized.
Early administration of lumasiran: after PH1 diagnosis, lumasiran is started early, before renal function decline occurs, to normalize or minimize urinary oxalate and thereby prevent stone formation and renal function decline. In pyridoxine responders, pyridoxine is given first, and if the response is insufficient, lumasiran is added or switched to.
Dietary education: intake of high-oxalate foods (spinach, nuts, tea, chocolate, beets) is restricted. Adequate calcium intake minimizes intestinal oxalate absorption (calcium binds oxalate in the gut and is excreted in the stool). Magnesium hydroxide may help inhibit stones.
Regular monitoring: renal function (GFR, creatinine), 24-hour urine oxalate, plasma oxalate, renal ultrasound (surveillance for stones and calcification), and ECG/echocardiography (surveillance for systemic oxalosis) are performed regularly. In particular, once renal function begins to decline, referral to a specialized center is needed to evaluate the indication for liver-kidney transplantation.